• Je něco špatně v tomto záznamu ?

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

R. Obermannová, E. Van Cutsem, T. Yoshino, G. Bodoky, J. Prausová, R. Garcia-Carbonero, T. Ciuleanu, P. Garcia Alfonso, D. Portnoy, A. Cohn, K. Yamazaki, P. Clingan, S. Lonardi, TW. Kim, L. Yang, F. Nasroulah, J. Tabernero,

. 2016 ; 27 (11) : 2082-2090. [pub] 20160829

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016960

BACKGROUND: The RAISE phase III clinical trial demonstrated that ramucirumab + FOLFIRI improved overall survival (OS) [hazard ratio (HR) = 0.844, P = 0.0219] and progression-free survival (PFS) (HR = 0.793, P < 0.0005) compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma (mCRC) patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. Since some patient or disease characteristics could be associated with differential efficacy or safety, prespecified subgroup analyses were undertaken. This report focuses on three of the most relevant ones: KRAS status (wild-type versus mutant), age (<65 versus ≥65 years), and time to progression (TTP) on first-line therapy (<6 versus ≥6 months). PATIENTS AND METHODS: OS and PFS were evaluated by the Kaplan-Meier analysis, with HR determined by the Cox proportional hazards model. Treatment-by-subgroup interaction was tested to determine whether treatment effect was consistent between subgroup pairs. RESULTS: Patients with both wild-type and mutant KRAS benefited from ramucirumab + FOLFIRI treatment over placebo + FOLFIRI (interaction P = 0.526); although numerically, wild-type KRAS patients benefited more (wild-type KRAS: median OS = 14.4 versus 11.9 months, HR = 0.82, P = 0.049; mutant KRAS: median OS = 12.7 versus 11.3 months, HR = 0.89, P = 0.263). Patients with both longer and shorter first-line TTP benefited from ramucirumab (interaction P = 0.9434), although TTP <6 months was associated with poorer OS (TTP ≥6 months: median OS = 14.3 versus 12.5 months, HR = 0.86, P = 0.061; TTP <6 months: median OS = 10.4 versus 8.0 months, HR = 0.86, P = 0.276). The subgroups of patients ≥65 versus <65 years also derived a similar ramucirumab survival benefit (interaction P = 0.9521) (≥65 years: median OS = 13.8 versus 11.7 months, HR = 0.85, P = 0.156; <65 years: median OS = 13.1 versus 11.9 months, HR = 0.86, P = 0.098). The safety profile of ramucirumab + FOLFIRI was similar across subgroups. CONCLUSIONS: These analyses revealed similar efficacy and safety among patient subgroups with differing KRAS mutation status, longer or shorter first-line TTP, and age. Ramucirumab is a beneficial addition to second-line FOLFIRI treatment for a wide range of patients with mCRC. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01183780.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016960
003      
CZ-PrNML
005      
20180515103345.0
007      
ta
008      
180515s2016 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/annonc/mdw402 $2 doi
035    __
$a (PubMed)27573561
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Obermannová, R $u Masaryk Memorial Cancer Institute, Brno, Czech Republic obermannova@mou.cz.
245    10
$a Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / $c R. Obermannová, E. Van Cutsem, T. Yoshino, G. Bodoky, J. Prausová, R. Garcia-Carbonero, T. Ciuleanu, P. Garcia Alfonso, D. Portnoy, A. Cohn, K. Yamazaki, P. Clingan, S. Lonardi, TW. Kim, L. Yang, F. Nasroulah, J. Tabernero,
520    9_
$a BACKGROUND: The RAISE phase III clinical trial demonstrated that ramucirumab + FOLFIRI improved overall survival (OS) [hazard ratio (HR) = 0.844, P = 0.0219] and progression-free survival (PFS) (HR = 0.793, P < 0.0005) compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma (mCRC) patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. Since some patient or disease characteristics could be associated with differential efficacy or safety, prespecified subgroup analyses were undertaken. This report focuses on three of the most relevant ones: KRAS status (wild-type versus mutant), age (<65 versus ≥65 years), and time to progression (TTP) on first-line therapy (<6 versus ≥6 months). PATIENTS AND METHODS: OS and PFS were evaluated by the Kaplan-Meier analysis, with HR determined by the Cox proportional hazards model. Treatment-by-subgroup interaction was tested to determine whether treatment effect was consistent between subgroup pairs. RESULTS: Patients with both wild-type and mutant KRAS benefited from ramucirumab + FOLFIRI treatment over placebo + FOLFIRI (interaction P = 0.526); although numerically, wild-type KRAS patients benefited more (wild-type KRAS: median OS = 14.4 versus 11.9 months, HR = 0.82, P = 0.049; mutant KRAS: median OS = 12.7 versus 11.3 months, HR = 0.89, P = 0.263). Patients with both longer and shorter first-line TTP benefited from ramucirumab (interaction P = 0.9434), although TTP <6 months was associated with poorer OS (TTP ≥6 months: median OS = 14.3 versus 12.5 months, HR = 0.86, P = 0.061; TTP <6 months: median OS = 10.4 versus 8.0 months, HR = 0.86, P = 0.276). The subgroups of patients ≥65 versus <65 years also derived a similar ramucirumab survival benefit (interaction P = 0.9521) (≥65 years: median OS = 13.8 versus 11.7 months, HR = 0.85, P = 0.156; <65 years: median OS = 13.1 versus 11.9 months, HR = 0.86, P = 0.098). The safety profile of ramucirumab + FOLFIRI was similar across subgroups. CONCLUSIONS: These analyses revealed similar efficacy and safety among patient subgroups with differing KRAS mutation status, longer or shorter first-line TTP, and age. Ramucirumab is a beneficial addition to second-line FOLFIRI treatment for a wide range of patients with mCRC. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01183780.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x aplikace a dávkování $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a kamptothecin $x aplikace a dávkování $x analogy a deriváty $7 D002166
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x patologie $7 D015179
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x aplikace a dávkování $7 D005472
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a leukovorin $x aplikace a dávkování $7 D002955
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a protoonkogenní proteiny p21(ras) $x genetika $7 D016283
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Van Cutsem, E $u University Hospitals Leuven and KU Leuven, Leuven, Belgium.
700    1_
$a Yoshino, T $u Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
700    1_
$a Bodoky, G $u Department of Oncology, St László Hospital, Budapest, Hungary.
700    1_
$a Prausová, J $u Onocology Clinic, Charles University, Prague, Czech Republic.
700    1_
$a Garcia-Carbonero, R $u Department of Oncology, Hospital Universitario Doce de Octubre, Madrid, Spain.
700    1_
$a Ciuleanu, T $u Institutul Oncologic Ion Chiricuta and UMF, Cluj-Napoca, Romania.
700    1_
$a Garcia Alfonso, P $u Department of Oncology, Hospital General Universitario Gregorio Maraňón, Madrid, Spain.
700    1_
$a Portnoy, D $u The West Clinic-University of Tennessee Health Sciences Center, Memphis.
700    1_
$a Cohn, A $u Rocky Mountain Cancer Center, Denver, USA.
700    1_
$a Yamazaki, K $u Department of Gastrointestinal Oncology, Shizouka Cancer Center, Shizouka, Japan.
700    1_
$a Clingan, P $u Southern Medical Day Care Centre, Wollongong, NSW, Australia.
700    1_
$a Lonardi, S $u Department of Medical Oncology, Istituto Oncologico Veneto-IRCCS, Padova, Italy.
700    1_
$a Kim, T W $u Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
700    1_
$a Yang, L $u Eli Lilly and Company, Bridgewater, USA.
700    1_
$a Nasroulah, F $u Eli Lilly and Company, Buenos Aires, Argentine Republic.
700    1_
$a Tabernero, J $u Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
773    0_
$w MED00000432 $t Annals of oncology official journal of the European Society for Medical Oncology $x 1569-8041 $g Roč. 27, č. 11 (2016), s. 2082-2090
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27573561 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103519 $b ABA008
999    __
$a ok $b bmc $g 1300584 $s 1013800
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 27 $c 11 $d 2082-2090 $e 20160829 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace